The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

Batalla, Albert; Janssen, Hella; Gangadin, Shiral S.; Bossong, Matthijs G.

doi:10.3390/jcm8071058

Cited by 67 publications

(54 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A systematic review providing evidence from clinical studies, mainly randomized clinical trial and case series, on the efficacy of CBD in the treatment of schizophrenia and/or substance abuse disorders observed large differences in study population, doses and administration [45]. In the present review, two principal outcomes were considered for schizophrenia patients, psychotic symptoms and cognitive functioning.…”

Section: Discussionmentioning

confidence: 99%

Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials

Larsen¹,

Shahinas²

2020

J Clin Med Res

121

View full text Add to dashboard Cite

Considering data from in vitro and in vivo studies, cannabidiol (CBD) seems to be a promising candidate for the treatment of both somatic and psychiatric disorders. The aim of this review was to collect dose(s), dosage schemes, efficacy and safety reports of CBD use in adults from clinical studies. A systematic search was performed in PubMed, Embase and Cochrane library for articles published in English between January 1, 2000 and October 25, 2019. The search terms used were related to cannabis and CBD in adults. We identified 25 studies (927 patients; 538 men and 389 women), of which 22 studies were controlled clinical trials (833 patients) and three were observational designs (94 patients) from five countries. Formulations, dose and dosage schemes varied significantly between studies. Varying effects were identified from the randomized controlled trials (RCTs), more apparent effects from non-RCTs and minor safety issues in general. From the controlled trials, we identified anxiolytic effects with acute CBD administration, and therapeutic effects for social anxiety disorder, psychotic disorder and substance use disorders. In general, studies were heterogeneous and showed substantial risks of bias. Although promising results have been identified, considerable variation in dosage schemes and route of administration were employed across studies. There was evidence to support single dose positive effect on social anxiety disorder, short medium-term effects on symptomatic improvement in schizophrenia and lack of effect in the short mediumterm on cognitive functioning in psychotic disorders. Overall, the administration was well tolerated with mild side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials

Larsen¹,

Shahinas²

2020

J Clin Med Res

121

View full text Add to dashboard Cite

show abstract

“…Future studies should focus on developing methods to identify those individuals with either resilient or vulnerable genotypes, while considering cannabis use within the whole exposome [101]. In addition, the biological mechanisms underlying the influence of cannabis on psychosis risk remain largely unclear [3,30]. Study of the endocannabinoid system might help to find new markers of illness and recovery, and identify new routes for the development of novel treatments [30].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the biological mechanisms underlying the influence of cannabis on psychosis risk remain largely unclear [3,30]. Study of the endocannabinoid system might help to find new markers of illness and recovery, and identify new routes for the development of novel treatments [30]. Importantly, CBD, a non-intoxicating compound of cannabis, has shown promising effects in individuals with psychotic symptoms [29,102,103].…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, a lower age of onset of cannabis use [17,19,21] and the use of more potent types of cannabis, with higher THC and lower cannabidiol (CBD) concentrations [22,28], have been shown to further increase the risk of psychosis. CBD is a non-intoxicating cannabinoid compound that may attenuate some of the negative effects associated with cannabis use [29][30][31]. The genetic profile of cannabis users has also been implicated as a moderator of the association between cannabis use and the development of psychosis [32][33][34].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Factors Moderating the Association between Cannabis Use and Psychosis Risk: A Systematic Review

2020

Self Cite

View full text Add to dashboard Cite

Increasing evidence indicates a relationship between cannabis use and psychosis risk. Specific factors, such as determinants of cannabis use or the genetic profile of cannabis users, appear to moderate this association. The present systematic review presents a detailed and up-to-date literature overview on factors that influence the relationship between cannabis use and psychosis risk. A systematic search was performed according to the PRISMA guidelines in MEDLINE and Embase, and 56 studies were included. The results show that, in particular, frequent cannabis use, especially daily use, and the consumption of high-potency cannabis are associated with a higher risk of developing psychosis. Moreover, several genotypes moderate the impact of cannabis use on psychosis risk, particularly those involved in the dopamine function, such as AKT1. Finally, cannabis use is associated with an earlier psychosis onset and increased risk of transition in individuals at a clinical high risk of psychosis. These findings indicate that changing cannabis use behavior could be a harm reduction strategy employed to lower the risk of developing psychosis. Future research should aim to further develop specific biomarkers and genetic profiles for psychosis, thereby contributing to the identification of individuals at the highest risk of developing a psychotic disorder.

show abstract

“…Other studies investigating the chronic effects of cannabis use have been conducted in participants diagnosed with schizophrenia, as one third of schizophrenia patients report using cannabis daily [ 115 ]. These individuals experience more severe psychotic symptoms in response to ∆-9-THC [ 116 ], whereas the antipsychotic properties of cannabidiol (CBD) improves symptoms of schizophrenia [ 117 , 118 ]. Schizophrenia patients comorbid for cannabis abuse demonstrate increased ICF and reduced SICI compared to schizophrenia patients that do not use cannabis [ 107 ].…”

Section: Cannabismentioning

confidence: 99%

The Influence of Recreational Substance Use in TMS Research

2020

View full text Add to dashboard Cite

(1) Background: Transcranial magnetic stimulation (TMS) approaches are widely used to study cortical and corticospinal function. However, responses to TMS are subject to significant intra-and inter-individual variability. Acute and chronic exposure to recreational substances alters the excitability of the sensorimotor system and may contribute to the variability in TMS outcome measures. The increasing prevalence of recreational substance use poses a significant challenge for executing TMS studies, but there is a lack of clarity regarding the influence of these substances on sensorimotor function. (2) Methods: The literature investigating the influence of alcohol, nicotine, caffeine and cannabis on TMS outcome measures of corticospinal, intracortical and interhemispheric excitability was reviewed. (3) Results: Both acute and chronic use of recreational substances modulates TMS measures of excitability. Despite the abundance of research in this field, we identify knowledge gaps that should be addressed in future studies to better understand the influence of these substances on TMS outcomes. (4) Conclusions: This review highlights the need for TMS studies to take into consideration the history of participant substance use and to control for acute substance use prior to testing.

show abstract

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

Cited by 67 publications

References 70 publications

Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials

Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials

Factors Moderating the Association between Cannabis Use and Psychosis Risk: A Systematic Review

The Influence of Recreational Substance Use in TMS Research

Contact Info

Product

Resources

About